Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The hypothesis of the study is that individuals with poor pulmonary function secondary to TIS will benefit from expansion thoracoplasty. The investigators specific aims are to:
Record pulmonary function and thoracic volume of TIS patients at enrollment and with serial observation
Offer expansion thoracoplasty therapy to TIS patients with
Document efficacy of expansion thoracoplasty for TIS patients
Study procedures
Patient Identification & Enrollment Patients meeting the inclusion criteria will be invited to enroll in the study as described above.
Serial clinical observation
Patients will be followed over time for progression of thoracic insufficiency indicators:
Patients with progressive thoracic insufficiency will be offered surgical intervention with expansion thoracoplasty utilizing the VEPTR device.
Studies which are standard of care for TIS will be utilized to assess patients. Routine standard of care studies will be obtained:
i.Xrays will be obtained every 6 months in association with the VEPTR lengthening.
ii.Once VEPTR lengthening is no longer clinically indicated, the patients will be followed with xrays every 6-24 months until skeletal maturity.
d.Pulmonary function tests (spirometry) will be obtained every 6-12 months in children who are old enough to participate (typically > age 4 years).
e.Arterial and/or capillary blood gases
a.Blood gases will be obtained every 6-12 months if clinically indicated and perioperatively for VEPTR implantation / lengthening.
f.Routine vital signs including resting pulse oximetry (SaO2)
a.Will be assessed at clinic visits and perioperatively g.All of the above mentioned studies will be obtained more or less frequently as clinically indicated.
Expansion thoracoplasty with VEPTR implantation and subsequent lengthening with the VEPTR will be performed following informed consent. The surgical technique will be as described by Campbell.3 The VEPTR device will be lengthened at 6 to 12 month intervals until thoracic and spinal deformities have stabilized radiographically.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Expansion Thoracoplasty | The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib) | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pulmonary function and thoracic volume of TIS patients | 1)Record pulmonary function and thoracic volume of TIS patients at enrollment and with serial observation postoperatively (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.) | Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.) |
| ffer expansion thoracoplasty therapy to TIS patients meeting certain criteria (provided in description below) | Offer expansion thoracoplasty therapy to TIS patients with
| Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.) |
| Document efficacy of expansion thoracoplasty for TIS patients | Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.) |
Not provided
Not provided
Inclusion Criteria:
Pediatric patients, age range from 6 months - 17 years with thoracic insufficiency syndrome (TIS) will be considered for inclusion. Categories of TIS include:
Exclusion Criteria:
Not provided
Not provided
Pediatric patients, age range from 6 months to 17 years with thoracic insufficiency syndrome (TIS). Categories of TIS include:
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeffrey Martus, MD | Vanderbilt University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Monroe Carell Jr. Children's Hospital at Vanderbilt | Nashville | Tennessee | 37232 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided